This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nielsen, S. Articles by Dandona, P. Search for Related Content PubMed PubMed Citation Articles by Nielsen, S. Articles by Dandona, P. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Diabetes Social Bookmarking                         What's this?

Use of Continuous Subcutaneous Insulin Infusion Pump in Patients With Type 2 Diabetes Mellitus

From the Division of Endocrinology, Diabetes and Metabolism, State University of New York and Kaleida Health, Buffalo, New York.

Correspondence to Paresh Dandona, MD, DPhil, FRCP, FACP, FACC, Millard Fillmore Hospital, 3 Gates Circle, Buffalo, NY 14209 (pdandona{at}kaleidahealth.org).

Purpose

In patients with type 2 diabetes, the control of hyperglycemia is often difficult despite full doses of oral hypoglycemic agents and extremely large doses of insulin. These patients pose a major management problem. The authors therefore investigated whether insulin given as a subcutaneous continuous infusion of insulin (CSII) would result in an improvement in glucose homeostasis.

Methods

Four patients with badly controlled type 2 diabetes, on treatment with extremely high doses of insulin and oral hypoglycemic agents, were started on CSII.

Results

All four patients had a marked improvement in plasma glucose concentrations with a corresponding fall in HbA1c levels. This improvement was associated with a marked fall in the insulin doses necessary to maintain adequate glucose homeostasis.

Conclusions

Since HbA1c levels fell from levels that would be associated with diabetic complications to those at which complications are markedly reduced, we recommendthat patients with type 2 diabetes uncontrolled on extremely high doses of insulin be given a trial of treatment with CSII.

The Diabetes Educator, Vol. 31, No. 6, 843-848 (2005)
DOI: 10.1177/0145721705283078


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. S. Skyler, S. Ponder, D. F. Kruger, D. Matheson, and C. G. Parkin Is There a Place for Insulin Pump Therapy in Your Practice? Clin. Diabetes, April 1, 2007; 25(2): 50 - 56. [Abstract] [Full Text] [PDF]